Strong Memorial Hospital
- Type
- Teaching hospital
- Where
- Rochester, NY
- Medicare CCN
- 330285
- Received
- $25,951,710 in 1,659 records, 2020 ($2,858,583 general, $23,093,127 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
- Lobbying client: STRONG MEMORIAL HOSPITAL Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 213 | $2,858,583 |
| 2020 | Research payment | 1,446 | $23,093,127 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 1,446 | $23,093,127 |
| Grant | 33 | $1,226,933 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 36 | $743,418 |
| Education | 25 | $354,418 |
| Royalty or License | 43 | $281,562 |
| Consulting Fee | 24 | $143,917 |
| Space rental or facility fees (teaching hospital only) | 37 | $98,374 |
| Gift | 11 | $5,759 |
| Charitable Contribution | 4 | $4,200 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Intuitive Surgical, Inc. | $63,440 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $49,216 | Research payment | In-kind items and services | LYNPARZA Drug, Oncology | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Pla | 2020 |
| 2020-12-31 | Kite Pharma, Inc. | $17,641 | Research payment | Cash or cash equivalent | A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with R | 2020 | |
| 2020-12-31 | Intuitive Surgical, Inc. | $13,750 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $9,773 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Co | 2020 |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $8,845 | Research payment | In-kind items and services | Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum Resistant Ovaria | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $4,881 | Research payment | Cash or cash equivalent | S3000 HELX with Touch Control Device, US - Ultrasound Systems | Advanced ARFI Research | 2020 |
| 2020-12-31 | Janssen Research & Development, LLC | $3,906 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | Pilot trial of Ustekinumab for Primary Sjogren's Syndrome | 2020 |
| 2020-12-31 | Intuitive Surgical, Inc. | $3,400 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $2,063 | Research payment | Cash or cash equivalent | UR2019MRIPR992Kwok | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $1,823 | Research payment | Cash or cash equivalent | UR2018IPR990844Weinberg | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $1,139 | Research payment | In-kind items and services | IMFINZI Drug, Oncology | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with | 2020 |
| 2020-12-31 | AstraZeneca UK Limited | $559 | Research payment | In-kind items and services | A Platform Protocol for the Treatment of Relapsed /Refractory Aggressive Non-Hodgkin's Lymphoma | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $524 | Research payment | Cash or cash equivalent | UR2019MRIPR794Tawil | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $393 | Research payment | Cash or cash equivalent | URochester2020MRIPR794Tawil | 2020 | |
| 2020-12-31 | BIOTRONIK INC. | $300 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $241 | Research payment | Cash or cash equivalent | UR2020MRIPR990Weinberg | 2020 | |
| 2020-12-31 | Aimmune Therapeutics, Inc. | $18 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-30 | Smith+Nephew, Inc. | $2,400 | Research payment | Cash or cash equivalent | BIRMINGHAM HIP Device, Recon Hips | A Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review | 2020 |
| 2020-12-28 | PFIZER INC. | $107,743 | Research payment | Cash or cash equivalent | PROTOCOLCDC MULTIPLIER STUDY PROJECT | 2020 | |
| 2020-12-25 | PFIZER INC. | $1,672 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-24 | Janssen Research & Development, LLC | $114,598 | Research payment | Cash or cash equivalent | Research Funding Agreement between Janssen Research & Development, LLC and The University of Rochester | 2020 | |
| 2020-12-24 | Merck Sharp & Dohme LLC | $2,768 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-24 | Merck Sharp & Dohme LLC | $1,882 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-24 | Intercept Pharmaceuticals, Inc. | $819 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-12-23 | JAZZ PHARMACEUTICALS INC. | $76,217 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-12-23 | Carestream Health, Inc. | $20,178 | Research payment | In-kind items and services | Medical Imaging Device, Medical Devices and Health Care Solutions | Preclinical Prototype Development Transcranial Ultrasound Image Probe | 2020 |
| 2020-12-23 | Gilead Sciences, Inc. | $2,252 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilof | 2020 | |
| 2020-12-23 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome | 2020 | |
| 2020-12-22 | Fresenius USA Marketing, Inc. | $65,257 | Research payment | Cash or cash equivalent | Mechanism of FG23 Regulation by Metabolic Acidosis | 2020 | |
| 2020-12-22 | Genentech, Inc. | $6,250 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | A PHASE III MULTICENTER OBSERVATION COMPARATOR STUDY OF THE EFFICACY SAFETY AND PHARMACOKINETICS | 2020 |
| 2020-12-22 | United Therapeutics Corporation | $5,451 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-12-22 | BioMarin Pharmaceutical Inc. | $5,000 | Research payment | Cash or cash equivalent | Brineura Biological, CLN 2 | Cerliponase alfa Observational Study US) | 2020 |
| 2020-12-22 | EMD Serono, Inc. | $2,111 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-12-22 | SEAGEN INC. | $188 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and | 2020 |
| 2020-12-22 | SEAGEN INC. | $4 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and | 2020 |
| 2020-12-21 | SANOFI US SERVICES INC. | $6,796 | Research payment | Cash or cash equivalent | DUPIXENT Biological, Immunology | Master Protocol of Two Randomized, Double-blind, Placebo Controlled, Multi-center, Parallel-group Studies of Dupilumab i | 2020 |
| 2020-12-21 | Boston Scientific Corporation | $1,560 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-12-21 | Pharmacyclics LLC, an AbbVie Company | $583 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1145-LT | 2020 |
| 2020-12-18 | Janssen Research & Development, LLC | $11,674 | Research payment | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | Procoagulant Extracellular Vesicles in PAH | 2020 |
| 2020-12-18 | PFIZER INC. | $4,221 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-18 | Janssen Research & Development, LLC | $390 | Research payment | Cash or cash equivalent | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Lo | 2020 | |
| 2020-12-17 | PFIZER INC. | $5,668 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPI | 2020 | |
| 2020-12-17 | Neurocrine BioSciences, Inc. | $595 | Consulting Fee | Cash or cash equivalent | 2020 | ||
| 2020-12-17 | Regeneron Pharmaceuticals, Inc. | $194 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-12-17 | Merck Sharp & Dohme LLC | $99 | Research payment | In-kind items and services | MK-5475 Drug, CARDIOVASCULAR | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose MK-5475 in Participan | 2020 |
| 2020-12-16 | BeiGene, Ltd. | $46,980 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patient | 2020 |
| 2020-12-16 | Roche TCRC, Inc. | $1,818 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHASE II STUDY IN EARLY STAGE PARKINSON S DISEASE PATIENTS | 2020 |
| 2020-12-16 | Biohaven Pharmaceuticals, Inc. | $1,653 | Research payment | Cash or cash equivalent | A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of Troriluzole in Adult Subjects with Spinocerebella | 2020 | |
| 2020-12-16 | Merck Sharp & Dohme LLC | $733 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2020 |
| 2020-12-16 | PFIZER INC. | $705 | Research payment | Cash or cash equivalent | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY | 2020 | |
| 2020-12-15 | Helsinn Therapeutics (U.S.), Inc. | $40,690 | Research payment | Cash or cash equivalent | AKYNZEO Drug, ONCOLOGY | Treatment of Refractory Nausea | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $12,874 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1116-CA | 2020 |
| 2020-12-15 | Incyte Corporation | $10,152 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxoliti | 2020 | |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $9,338 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1145-LT | 2020 |
| 2020-12-15 | Aimmune Therapeutics, Inc. | $5,818 | Research payment | Cash or cash equivalent | PALFORZIA Biological, ALLERGY | A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS | 2020 |
| 2020-12-15 | Takeda Pharmaceuticals U.S.A., Inc. | $4,264 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACI | 2020 | |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $2,275 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1145-LT | 2020 |
| 2020-12-15 | Pharmacyclics LLC, an AbbVie Company | $2,000 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1145-LT | 2020 |
| 2020-12-15 | C. R. Bard, Inc. & Subsidiaries | $2,000 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-12-14 | Merck Sharp & Dohme LLC | $65,139 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-14 | Merck Sharp & Dohme LLC | $39,083 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-14 | Janssen Research & Development, LLC | $6,332 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | Pilot trial of Ustekinumab for Primary Sjogren's Syndrome | 2020 |
| 2020-12-14 | Genentech, Inc. | $4,788 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY FOR MODERATE AD | 2020 |
| 2020-12-14 | Merck Sharp & Dohme LLC | $657 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2020 |
| 2020-12-12 | Amgen Inc. | $10,200 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-12-11 | Merck Sharp & Dohme LLC | $1,147 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus | 2020 |
| 2020-12-11 | PFIZER INC. | $860 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-10 | SANOFI PASTEUR INC. | $123,844 | Research payment | Cash or cash equivalent | VAT00001 Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (with or without adjuvant) in | 2020 | |
| 2020-12-10 | Kite Pharma, Inc. | $15,499 | Research payment | Cash or cash equivalent | Yescarta Drug, CELLT | A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Thera | 2020 |
| 2020-12-10 | Merck Sharp & Dohme LLC | $13,027 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Adjuvant Therapy with Pembrolizumab versus Placebo in Resected High Risk Stage II Melanoma A Randomized, Double-blind Ph | 2020 |
| 2020-12-10 | Genentech, Inc. | $12,109 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | POLARIX | 2020 |
| 2020-12-10 | Organ Recovery Systems, Inc. | $7,319 | Research payment | Cash or cash equivalent | PILOT | 2020 | |
| 2020-12-10 | Pharmacyclics LLC, an AbbVie Company | $5,351 | Research payment | Cash or cash equivalent | Imbruvica Drug, Oncology | PCYC-1142-CA | 2020 |
| 2020-12-10 | Genentech, Inc. | $4,435 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY OF ANTI TAU IN PRODROMAL TO MILD AD | 2020 |
| 2020-12-10 | EMD Serono, Inc. | $2,221 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-12-10 | Regeneron Pharmaceuticals, Inc. | $1,369 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-12-10 | Incyte Corporation | $1,145 | Research payment | Cash or cash equivalent | A Phase 1-2, Open-Label Study of the JAK2 Inhibitor INCB018424 Administered Orally to Patients With Primary Myelofibrosi | 2020 | |
| 2020-12-09 | PFIZER INC. | $12,400 | Research payment | Cash or cash equivalent | DAURISMO Drug, ONCOLOGY | A RANDOMIZED 11 DOUBLEBLIND MULTICENTER PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASD | 2020 |
| 2020-12-08 | Octapharma USA, Inc. | $15,541 | Research payment | Cash or cash equivalent | OCTAPLAS Biological, INTENSIVE CAREEMERGENCY | OCTAPLAS IIS STUDY | 2020 |
| 2020-12-08 | Octapharma USA, Inc. | $15,541 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2020 | ||
| 2020-12-08 | Genentech, Inc. | $14,522 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-12-08 | Karyopharm Therapeutics Inc. | $5,144 | Research payment | Cash or cash equivalent | XPOVIO Drug, Oncology | KCP-330-017A | 2020 |
| 2020-12-08 | BioMarin Pharmaceutical Inc. | $4,250 | Research payment | Cash or cash equivalent | Kuvan Drug, PKU | PKU Demographics, Outcomes, and Safety Registry | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $3,750 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $289 | Research payment | Cash or cash equivalent | A PHASE 2, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF THE EFFICACY AND SAFETY OF PEVONEDISTAT PLUS AZACITIDIN | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $256 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $256 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $256 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $235 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $235 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | Medical Device Business Services, Inc. | $225 | Research payment | Cash or cash equivalent | ENTERPRISE Device, Neurosurgery | A Prospective, Multi-center, Single Arm Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE Vascular | 2020 |
| 2020-12-08 | BIOTRONIK INC. | $214 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $214 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $214 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $208 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | Incyte Corporation | $176 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $126 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $126 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $126 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | Incyte Corporation | $98 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $63 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $63 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | Incyte Corporation | $57 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $42 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $42 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $42 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | Incyte Corporation | $34 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-08 | Incyte Corporation | $22 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | BIOTRONIK INC. | $21 | Research payment | Cash or cash equivalent | BIO-LIBRA | 2020 | |
| 2020-12-08 | Merck Sharp & Dohme LLC | $20 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With | 2020 | |
| 2020-12-07 | Merck Sharp & Dohme LLC | $32,569 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2020 |
| 2020-12-07 | Merck Sharp & Dohme LLC | $1,845 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in comb | 2020 |
| 2020-12-04 | NeuroMetrix Inc | $4,454 | Research payment | Cash or cash equivalent | Quell Device, Pain Management | Quell Pain Management System for Reducing Chronic Chemotherapy-induced Peripheral Neuropathic Pain | 2020 |
| 2020-12-04 | Merck Sharp & Dohme LLC | $2,547 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2020 |
| 2020-12-04 | PFIZER INC. | $1,339 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-12-03 | Alcon Research LLC | $250,000 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-12-03 | JAZZ PHARMACEUTICALS INC. | $76,217 | Research payment | In-kind items and services | VYXEOS Drug, HEMATOLOGY/ONCOLOGY | A STUDY TO COMPARE STANDARD CHEMOTHERAPY TO THERAPY WITH CPX-351 AND/OR GILTERITINIB FOR PATIENTS WITH NEWLY DIAGNOSED A | 2020 |
| 2020-12-03 | SANOFI PASTEUR INC. | $35,420 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-12-03 | BeiGene, Ltd. | $18,792 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patient | 2020 |
| 2020-12-03 | Amgen Inc. | $10,200 | Research payment | In-kind items and services | Otezla Drug, Inflammation | Efficacy Safety Tolerability Study of Apremilast to Treat Early Oligoarticular PSA (PSA-013) | 2020 |
| 2020-12-03 | PFIZER INC. | $4,127 | Research payment | Cash or cash equivalent | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY | 2020 | |
| 2020-12-03 | Janssen Research & Development, LLC | $2,868 | Research payment | Cash or cash equivalent | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortez | 2020 | |
| 2020-12-03 | Genentech, Inc. | $1,440 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2020 |
| 2020-12-03 | PFIZER INC. | $705 | Research payment | Cash or cash equivalent | A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY | 2020 | |
| 2020-12-02 | Merck Sharp & Dohme LLC | $39,083 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, randomized, double-blind clinical study of pembrolizumab MK-3475 plus chemotherapy versus placebo plus chemot | 2020 |
| 2020-12-02 | Kite Pharma, Inc. | $18,432 | Research payment | Cash or cash equivalent | A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects with Relapsed/Refractory | 2020 | |
| 2020-12-02 | Merck Sharp & Dohme LLC | $4,153 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-02 | PFIZER INC. | $3,549 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB IN COMBINATION WITH BEMPEGALDESLEUKINNKTR214 WITH | 2020 |
| 2020-12-02 | Merck Sharp & Dohme LLC | $1,882 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-12-02 | Smith+Nephew, Inc. | $1,653 | Research payment | Cash or cash equivalent | BIRMINGHAM HIP Device, Recon Hips | A Post-Approval Study of the Birmingham Hip Resurfacing (BHR) Radiological System Review | 2020 |
| 2020-12-02 | Travere Therapeutics, Inc. | $645 | Research payment | Cash or cash equivalent | (820) Cholbam Drug, Hepatology | The Replace Registry | 2020 |
| 2020-12-01 | Sarepta Therapeutics, Inc. | $33,163 | Research payment | Cash or cash equivalent | Vyondys 53 Drug, Genetic Disease | 4045-301 | 2020 |
| 2020-12-01 | EMD Serono, Inc. | $650 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-12-01 | EMD Serono, Inc. | $500 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-11-30 | Johnson & Johnson Surgical Vision, Inc. | $75,000 | Royalty or License | Cash or cash equivalent | 2020 | ||
| 2020-11-30 | Merck Sharp & Dohme LLC | $1,505 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination wit | 2020 |
| 2020-11-30 | KARL STORZ Endoscopy-America | $64 | Education | In-kind items and services | TELESCOPE HOPKINS STRAIGHT, 0 Device, LAPAROSCOPY | 2020 | |
| 2020-11-30 | KARL STORZ Endoscopy-America | $64 | Education | In-kind items and services | TRAY, STERRAD, 2 RIGID SCOPES Device, CLEANING, STERILIZATION, CARE | 2020 | |
| 2020-11-30 | KARL STORZ Endoscopy-America | $62 | Education | In-kind items and services | CONVERTER, ANALOG -DIGITAL 1080P, DVI Device, OR1 | 2020 | |
| 2020-11-30 | KARL STORZ Endoscopy-America | $2 | Education | In-kind items and services | TRAY, STERRAD, 2 RIGID SCOPES Device, CLEANING, STERILIZATION, CARE | 2020 | |
| 2020-11-27 | Abbott Laboratories | $18,340 | Research payment | In-kind items and services | HeartMate 3 Left Ventricular Dev Device, Cardiac Arrhythmias and Heart Failure | Effects of Home-based Exercise Rehabilitation on Activity Levels in Left Ventricular Assist Device Patients | 2020 |
| 2020-11-26 | PFIZER INC. | $1,307 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-24 | Incyte Corporation | $82,089 | Research payment | Cash or cash equivalent | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxoliti | 2020 | |
| 2020-11-24 | United Therapeutics Corporation | $28,245 | Research payment | Cash or cash equivalent | Wearable Technology Improving Detection of Clinical Improvement in PAH | 2020 | |
| 2020-11-24 | Intercept Pharmaceuticals, Inc. | $7,598 | Research payment | Cash or cash equivalent | OCALIVA Drug, HEPATOLOGY GASTROENTEROLOGY | 1011866 | 2020 |
| 2020-11-24 | United Therapeutics Corporation | $5,287 | Research payment | Cash or cash equivalent | ORENITRAM Drug, PAH | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | 2020 |
| 2020-11-24 | United Therapeutics Corporation | $4,617 | Research payment | Cash or cash equivalent | REMODULIN Drug, PAH | ADAPT - A PATIENT REGISTRY OF THE REAL-WORLD USE OF ORENITRAM | 2020 |
| 2020-11-23 | Merck Sharp & Dohme LLC | $58,625 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-11-23 | Bayer Healthcare Pharmaceuticals Inc. | $1,599 | Research payment | Cash or cash equivalent | Adempas Drug, Cardio-pulmonary | Riociguat replacing PDE5i therapy | 2020 |
| 2020-11-23 | Merck Sharp & Dohme LLC | $755 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-11-21 | PFIZER INC. | $6,291 | Research payment | Cash or cash equivalent | A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO DEMONSTRATE THE EFFICACY AND LONGTERM SAFETY OF PF04965842 WITH TOPI | 2020 | |
| 2020-11-20 | Genentech, Inc. | $53,446 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GANTENERUMAB IN EARLY AD | 2020 |
| 2020-11-20 | PFIZER INC. | $2,549 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-19 | BeiGene, Ltd. | $28,188 | Research payment | In-kind items and services | BRUKINSA Drug, ONCOLOGY | An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patient | 2020 |
| 2020-11-19 | Medtronic Vascular, Inc. | $20,000 | Research payment | Cash or cash equivalent | Reveal LINQ Device, Cardiac Diagnostics and Monitoring | Investigator Sponsored Research | 2020 |
| 2020-11-19 | Genentech, Inc. | $11,126 | Research payment | Cash or cash equivalent | Drug | PHASE II STUDY FOR MODERATE AD | 2020 |
| 2020-11-19 | Medtronic USA, Inc. | $5,500 | Grant | Cash or cash equivalent | 2020 | ||
| 2020-11-19 | Merck Sharp & Dohme LLC | $887 | Research payment | In-kind items and services | MK-5475 Drug, CARDIOVASCULAR | A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose MK-5475 in Participan | 2020 |
| 2020-11-19 | Intercept Pharmaceuticals, Inc. | $819 | Research payment | Cash or cash equivalent | 1009742 | 2020 | |
| 2020-11-19 | Takeda Pharmaceuticals U.S.A., Inc. | $589 | Research payment | Cash or cash equivalent | A PHASE 2, LONG-TERM IMMUNOGENICITY FOLLOW-UP TRIAL OF ADULT AND ELDERLY SUBJECTS WHO HAVE PREVIOUSLY RECEIVED AN INTRAM | 2020 | |
| 2020-11-19 | Regeneron Pharmaceuticals, Inc. | $582 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEA | 2020 |
| 2020-11-19 | Olympus Corporation of the Americas | $150 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-11-19 | Merck Sharp & Dohme LLC | $74 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in comb | 2020 |
| 2020-11-18 | PFIZER INC. | $11,884 | Research payment | Cash or cash equivalent | BAVENCIO Drug, ONCOLOGY | A PHASE 1B2 STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB IN COMBINATION WITH BEMPEGALDESLEUKINNKTR214 WITH | 2020 |
| 2020-11-18 | Genentech, Inc. | $10,000 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | GANTENERUMAB IN EARLY AD | 2020 |
| 2020-11-18 | AQUESTIVE THERAPEUTICS, INC. | $1,716 | Research payment | Cash or cash equivalent | LIBERVANT Drug, Epilepsy | SAFETY AND TOLERABILITY STUDY OF DIAZEPAM BUCCAL SOLUBLE FILM DBSF IN SUBJECTS WITH EPILEPSY | 2020 |
| 2020-11-18 | Terumo BCT, Inc. | $1,200 | Research payment | Cash or cash equivalent | Mirasol Pathogen Reduction Technology System Device, Pathogen reduction | CTS 5056 PRAISE | 2020 |
| 2020-11-18 | AQUESTIVE THERAPEUTICS, INC. | $572 | Research payment | Cash or cash equivalent | LIBERVANT Drug, Epilepsy | SAFETY AND TOLERABILITY STUDY OF DIAZEPAM BUCCAL SOLUBLE FILM DBSF IN SUBJECTS WITH EPILEPSY | 2020 |
| 2020-11-18 | AQUESTIVE THERAPEUTICS, INC. | $122 | Research payment | Cash or cash equivalent | LIBERVANT Drug, Epilepsy | SAFETY AND TOLERABILITY STUDY OF DIAZEPAM BUCCAL SOLUBLE FILM DBSF IN SUBJECTS WITH EPILEPSY | 2020 |
| 2020-11-17 | Takeda Pharmaceuticals U.S.A., Inc. | $36,231 | Research payment | Cash or cash equivalent | A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACI | 2020 | |
| 2020-11-17 | EMD Serono, Inc. | $6,372 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-11-17 | Genentech, Inc. | $2,225 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PHII IL22 UC STUDY | 2020 |
| 2020-11-17 | Merck Sharp & Dohme LLC | $1,882 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-11-17 | Merck Sharp & Dohme LLC | $1,384 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for F | 2020 |
| 2020-11-17 | EMD Millipore Corporation | $539 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-11-16 | Boston Scientific Corporation | $3,767 | Research payment | Cash or cash equivalent | Resonate Device, Tachy | PREEMPT HF | 2020 |
| 2020-11-14 | PFIZER INC. | $1,721 | Research payment | Cash or cash equivalent | A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENIC | 2020 | |
| 2020-11-13 | Medtronic Vascular, Inc. | $995 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-11-13 | ABBVIE INC. | $647 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | M14-032 | 2020 |
| 2020-11-13 | Abbott Laboratories | $32 | Research payment | In-kind items and services | HeartMate 3 Device, Cardiac Arrhythmias and Heart Failure | Implantation of the HeartMate 3 in Subjects With Heart Failure Using Surgical Techniques Other Than Full Median Sternoto | 2020 |
| 2020-11-12 | Clovis Oncology, Inc. | $18,621 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
| 2020-11-12 | ABBVIE INC. | $3,077 | Research payment | Cash or cash equivalent | M16-837 | 2020 | |
| 2020-11-12 | EMD Serono, Inc. | $2,301 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-11-12 | EMD Serono, Inc. | $1,719 | Research payment | Cash or cash equivalent | M7824 (PD-L1 TRAP) | An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bintrafusp alfa) versus Pembroliz | 2020 |
| 2020-11-12 | Clovis Oncology, Inc. | $572 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Canc | 2020 |
The latest 200 records of 1,659.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Rochester, NY, county Monroe County, NY, state New York; placed by its city name.
| Measure | Place (city or town) Rochester, NY | County Monroe County, NY | State New York |
|---|---|---|---|
| Population B01003 | 208,772 | 753,753 | 19,852,366 |
| Population, 2020 census P1 | 211,328 | 759,443 | 20,201,249 |
| Median age B01002 | 33.7 | 39.6 | 39.8 |
| Under 18 B01001 | 20.9% | 20.3% | 20.5% |
| 65 and over B01001 | 13.1% | 18.8% | 17.9% |
| Households B11001 | 93,261 | 318,428 | 7,722,646 |
| Foreign born B05002 | 8.2% | 7.9% | 22.8% |
| Median household income B19013 | $47,213 | $76,382 | $85,974 |
| Median family income B19113 | $57,673 | $102,166 | $106,873 |
| Per capita income B19301 | $31,314 | $44,107 | $50,712 |
| Poverty rate B17001 | 27.8% | 13.6% | 14.0% |
| Unemployment rate B23025 | 7.9% | 4.9% | 6.4% |
| Civilian labor force B23025 | 105,136 | 391,197 | 10,171,766 |
| Mean commute (minutes) B08013 | 19.3 | 19.9 | 32.6 |
| Bachelor's degree or higher B15003 | 30.0% | 41.5% | 40.2% |
| Housing units B25001 | 104,479 | 339,430 | 8,585,241 |
| Owner-occupied B25003 | 38.1% | 63.7% | 54.3% |
| Renters B25003 | 61.9% | 36.3% | 45.7% |
| Median home value B25077 | $139,600 | $213,700 | $423,800 |
| Median gross rent B25064 | $1,081 | $1,173 | $1,621 |
| White, not Hispanic B03002 | 36.4% | 67.7% | 52.8% |
| Black B03002 | 34.7% | 13.5% | 13.4% |
| Hispanic or Latino B03002 | 19.6% | 9.9% | 19.8% |
| Asian B03002 | 3.2% | 3.8% | 9.0% |
| American Indian and Alaska Native B03002 | 0.2% | 0.1% | 0.2% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rochester, NY.
Comments